Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Nima Hooshdaran"'
Publikováno v:
Cell Reports, Vol 29, Iss 9, Pp 2702-2717.e7 (2019)
Summary: Although microRNAs (miRNAs) function in the control of embryonic stem cell (ESC) pluripotency, a systems-level understanding is still being developed. Through the analysis of progressive Argonaute (Ago)-miRNA depletion and rescue, including
Externí odkaz:
https://doaj.org/article/8d18ebdae34b458f9ec547a77a24f154
Autor:
Shalini Chopra, Kai Trepka, Sasank Sakhamuri, Alberto Carretero-González, Jun Zhu, Emily Egusa, Jie Zhou, Kevin Leung, Ning Zhao, Nima Hooshdaran, Felix Y. Feng, James A. Wells, Jonathan Chou, Michael J. Evans
Publikováno v:
Clinical Cancer Research. 29:1232-1242
Purpose: Despite recent approvals for checkpoint inhibitors and antibody–drug conjugates targeting NECTIN4 or TROP2, metastatic bladder cancer remains incurable and new treatment strategies are urgently needed. CUB domain–containing protein 1 (CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6363e01c1ad61a63689d1134cd2bbd86
https://doi.org/10.1158/1078-0432.ccr-22-1973
https://doi.org/10.1158/1078-0432.ccr-22-1973
Autor:
Michael J. Evans, Jonathan Chou, James A. Wells, Felix Y. Feng, Nima Hooshdaran, Ning Zhao, Kevin Leung, Jie Zhou, Emily Egusa, Jun Zhu, Alberto Carretero-González, Sasank Sakhamuri, Kai Trepka, Shalini Chopra
Purpose:Despite recent approvals for checkpoint inhibitors and antibody–drug conjugates targeting NECTIN4 or TROP2, metastatic bladder cancer remains incurable and new treatment strategies are urgently needed. CUB domain–containing protein 1 (CDC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db1177f1551e4aefa0dabda0ae25ee3
https://doi.org/10.1158/1078-0432.c.6533116
https://doi.org/10.1158/1078-0432.c.6533116
Autor:
Michael J. Evans, Jonathan Chou, James A. Wells, Felix Y. Feng, Nima Hooshdaran, Ning Zhao, Kevin Leung, Jie Zhou, Emily Egusa, Jun Zhu, Alberto Carretero-González, Sasank Sakhamuri, Kai Trepka, Shalini Chopra
CDCP1 mRNA is not correlated NECTIN4 or TROP2 mRNA, related to Figure 2C. Spearman correlation analyses were performed between CDCP1 and NECTIN4 or TROP2 for the Seiler, Sjodahl 2017, and Sjodahl 2012 datasets, with p values and correlation coefficie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2338289ccb4af9f0a384645c00056ca4
https://doi.org/10.1158/1078-0432.22495104.v1
https://doi.org/10.1158/1078-0432.22495104.v1
Autor:
Michael J. Evans, Jonathan Chou, James A. Wells, Felix Y. Feng, Nima Hooshdaran, Ning Zhao, Kevin Leung, Jie Zhou, Emily Egusa, Jun Zhu, Alberto Carretero-González, Sasank Sakhamuri, Kai Trepka, Shalini Chopra
CDCP1 mRNA is overexpressed in basal/squamous subtypes of bladder cancer, related to Figure 1A-D. Pairwise comparisons of CDCP1 expression between bladder cancer consensus subtypes using the Wilcoxon rank-sum test across four different datasets are s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2de8a902264c380b363c4d25919ffc2
https://doi.org/10.1158/1078-0432.22490197.v1
https://doi.org/10.1158/1078-0432.22490197.v1
Autor:
Hyunjung Kim, Yangjie Huang, Ning Zhao, Yung-hua Wang, Sasank Sakhamuri, Shalini Chopra, Nima Hooshdaran, Renuka Sriram, Rahul Aggarwal, Michael J. Evans
Publikováno v:
Molecular Pharmaceutics. 19:704-709
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6314b8cee928f3b4463dfcfa52fd6c1a
https://doi.org/10.1021/acs.molpharmaceut.1c00833
https://doi.org/10.1021/acs.molpharmaceut.1c00833
Autor:
Michael J. Evans, Rahul Aggarwal, James A. Wells, Jonathan Chou, Eric J. Small, Felix Y. Feng, Youngho Seo, Emily Chan, Renuka Sriram, Adam Foye, Li Zhang, Jun Zhu, Emily A. Egusa, Kevin K. Leung, Shion A. Lim, Jie Zhou, Hyunjung Kim, Nima Hooshdaran, Sasank Sakhamuri, Yung-Hua Wang, Kai Trepka, Shalini Chopra, Ning Zhao
Supplementary Table from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7202861d7ba2f0a879bfc4b29eba348
https://doi.org/10.1158/1078-0432.22486157.v1
https://doi.org/10.1158/1078-0432.22486157.v1
Autor:
Michael J. Evans, Rahul Aggarwal, James A. Wells, Jonathan Chou, Eric J. Small, Felix Y. Feng, Youngho Seo, Emily Chan, Renuka Sriram, Adam Foye, Li Zhang, Jun Zhu, Emily A. Egusa, Kevin K. Leung, Shion A. Lim, Jie Zhou, Hyunjung Kim, Nima Hooshdaran, Sasank Sakhamuri, Yung-Hua Wang, Kai Trepka, Shalini Chopra, Ning Zhao
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c57f6fa7feebd91bb46f1e618ae91cc
https://doi.org/10.1158/1078-0432.22486163.v1
https://doi.org/10.1158/1078-0432.22486163.v1
Autor:
Michael J. Evans, Rahul Aggarwal, James A. Wells, Jonathan Chou, Eric J. Small, Felix Y. Feng, Youngho Seo, Emily Chan, Renuka Sriram, Adam Foye, Li Zhang, Jun Zhu, Emily A. Egusa, Kevin K. Leung, Shion A. Lim, Jie Zhou, Hyunjung Kim, Nima Hooshdaran, Sasank Sakhamuri, Yung-Hua Wang, Kai Trepka, Shalini Chopra, Ning Zhao
Purpose:With the improvement in overall survival with 177Lu-PSMA 617, radioligand therapy (RLT) is now a viable option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, responses are variable, in part due to low PSMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b082113f876c3ce1134300d647cec0f
https://doi.org/10.1158/1078-0432.c.6532265.v1
https://doi.org/10.1158/1078-0432.c.6532265.v1
Autor:
Ryan L. Gonciarz, Sasank Sakhamuri, Nima Hooshdaran, Garima Kumar, Hyunjung Kim, Michael J. Evans, Adam R. Renslo
Publikováno v:
European Journal of Medicinal Chemistry. 249:115110
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::880edea0fcb32f940f89d062a0066631
https://doi.org/10.1016/j.ejmech.2023.115110
https://doi.org/10.1016/j.ejmech.2023.115110